These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 22897584)

  • 41. Characterization of hematopoietic stem cell subsets from patients with multiple myeloma after mobilization with plerixafor.
    Taubert I; Saffrich R; Zepeda-Moreno A; Hellwig I; Eckstein V; Bruckner T; Ho AD; Wuchter P
    Cytotherapy; 2011 Apr; 13(4):459-66. PubMed ID: 21077729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization.
    Smith VR; Popat U; Ciurea S; Nieto Y; Anderlini P; Rondon G; Alousi A; Qazilbash M; Kebriaei P; Khouri I; de Lima M; Champlin R; Hosing C
    Am J Hematol; 2013 Sep; 88(9):754-7. PubMed ID: 23749720
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Stimulation of adrenergic activity by desipramine enhances hematopoietic stem and progenitor cell mobilization along with G-CSF in multiple myeloma: A pilot study.
    Shastri A; Budhathoki A; Barta SK; Kornblum N; Derman O; Battini R; Raghupathy R; Verma AK; Frenette PS; Braunschweig I; Janakiram M
    Am J Hematol; 2017 Oct; 92(10):1047-1051. PubMed ID: 28675459
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Successful hematopoietic stem cell collection in patients who fail initial plerixafor mobilization for autologous stem cell transplant.
    Veeraputhiran M; Jain T; Cronin S; Al-Kadhimi Z; Abidi MH; Ayash L; Mellert K; Lum LG; Ratanatharathorn V; Uberti JP; Deol A
    J Clin Apher; 2014 Dec; 29(6):293-8. PubMed ID: 24700728
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Plerixafor added to chemotherapy plus G-CSF is safe and allows adequate PBSC collection in predicted poor mobilizer patients with multiple myeloma or lymphoma.
    Attolico I; Pavone V; Ostuni A; Rossini B; Musso M; Crescimanno A; Martino M; Iacopino P; Milone G; Tedeschi P; Coluzzi S; Nuccorini R; Pascale S; Di Nardo E; Olivieri A
    Biol Blood Marrow Transplant; 2012 Feb; 18(2):241-9. PubMed ID: 21791194
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pegylated granulocyte colony-stimulating factor mobilizes CD34+ cells with different stem and progenitor subsets and distinct functional properties in comparison with unconjugated granulocyte colony-stimulating factor.
    Bruns I; Steidl U; Fischer JC; Czibere A; Kobbe G; Raschke S; Singh R; Fenk R; Rosskopf M; Pechtel S; von Haeseler A; Wernet P; Tenen DG; Haas R; Kronenwett R
    Haematologica; 2008 Mar; 93(3):347-55. PubMed ID: 18268278
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.
    Duarte RF; Shaw BE; Marín P; Kottaridis P; Ortiz M; Morante C; Delgado J; Gayoso J; Goterriz R; Martínez-Chamorro C; Mateos-Mazón JJ; Ramírez C; de la Rubia J; Achtereekte H; Gandhi PJ; Douglas KW; Russell NH
    Bone Marrow Transplant; 2011 Jan; 46(1):52-8. PubMed ID: 20305700
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparison of Plerixafor or Cyclophosphamide Combined with G-CSF in Mobilization of Peripheral Blood Stem Cells in Multiple Myeloma].
    Li WT; Ma LM; Lian Y; Wang QG; Gao ZJ; Zhao S
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Oct; 31(5):1403-1409. PubMed ID: 37846691
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation.
    Pusic I; Jiang SY; Landua S; Uy GL; Rettig MP; Cashen AF; Westervelt P; Vij R; Abboud CN; Stockerl-Goldstein KE; Sempek DS; Smith AL; DiPersio JF
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1045-1056. PubMed ID: 18721768
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clonogenic potential and phenotypic analysis of CD34+ cells mobilized by different chemotherapy regimens.
    Cesana C; Regazzi E; Garau D; Caramatti C; Mangoni L; Rizzoli V
    Haematologica; 1999 Sep; 84(9):771-8. PubMed ID: 10477448
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Plerixafor in combination with granulocyte-colony-stimulating factor after chemotherapy increases mobilization efficiency in patients with lymphoma or myeloma: results of a Phase II clinical trial.
    Jagirdar N; Harvey RD; Nooka A; Flowers C; Kaufman J; Lonial S; Lechowicz MJ; Langston A; Lipscomb C; Gaylor C; Waller EK
    Transfusion; 2015 Oct; 55(10):2351-7. PubMed ID: 26331348
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma.
    Stewart DA; Smith C; MacFarland R; Calandra G
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):39-46. PubMed ID: 19135941
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Plerixafor on demand in ten healthy family donors as a rescue strategy to achieve an adequate graft for stem cell transplantation.
    Gattillo S; Marktel S; Rizzo L; Malato S; Malabarba L; Coppola M; Assanelli A; Milani R; De Freitas T; Corti C; Bellio L; Ciceri F
    Transfusion; 2015 Aug; 55(8):1993-2000. PubMed ID: 25721167
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Collection of more hematopoietic progenitor cells with large volume leukapheresis in patients with multiple myeloma.
    Desikan KR; Jagannath S; Siegel D; Nelson J; Bracy D; Barlogie B; Tricot G
    Leuk Lymphoma; 1998 Feb; 28(5-6):501-8. PubMed ID: 9613979
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hematopoietic progenitor cell mobilization using low-dose cyclophosphamide and granulocyte colony-stimulating factor for multiple myeloma.
    Shimura Y; Kuroda J; Uchiyama H; Kawata-Iida E; Tsutsumi Y; Nagoshi H; Mizutani S; Yamamoto-Sugitani M; Matsumoto Y; Kobayashi T; Horiike S; Shimazaki C; Kaneko H; Kobayashi Y; Taniwaki M
    J Clin Apher; 2013 Oct; 28(5):368-73. PubMed ID: 23804501
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Hematopoietic progenitor cell mobilization with "just-in-time" plerixafor approach is a cost-effective alternative to routine plerixafor use.
    Veltri L; Cumpston A; Shillingburg A; Wen S; Luo J; Leadmon S; Watkins K; Craig M; Hamadani M; Kanate AS
    Cytotherapy; 2015 Dec; 17(12):1785-92. PubMed ID: 26475754
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Optimization of mobilization regimes of blood hemopoietic stem cells in patients with multiple myeloma].
    Pokrovskaia OS; Mendeleeva LP; Urnova ES; Gaponova TV; Gribanova EO; Alekseeva IV; Drokov MIu; Kalinin NN; Gretsov EM; Kliasova GA; Savchenko VG
    Ter Arkh; 2011; 83(7):50-7. PubMed ID: 21894752
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Mobilization of peripheral blood stem cells for autologous transplant in non-Hodgkin's lymphoma and multiple myeloma patients by plerixafor and G-CSF and detection of tumor cell mobilization by PCR in multiple myeloma patients.
    Fruehauf S; Ehninger G; Hübel K; Topaly J; Goldschmidt H; Ho AD; Müller S; Moos M; Badel K; Calandra G
    Bone Marrow Transplant; 2010 Feb; 45(2):269-75. PubMed ID: 19597422
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Additional plerixafor to granulocyte colony-stimulating factors for haematopoietic stem cell mobilisation for autologous transplantation in people with malignant lymphoma or multiple myeloma.
    Hartmann T; Hübel K; Monsef I; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2015 Oct; 2015(10):CD010615. PubMed ID: 26484982
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.